Bladder Cancer Resources
Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Sponsored by Photocure, Inc.
Approximately 85,000 new cases of bladder cancer will be diagnosed in 2025. For most patients, bladder cancer is found with routine checkups without any severe symptoms. This often makes early detection difficult. But with research, clinical trials and new technology, novel treatments are on the way for patients.
Below are resources to help you stay up-to-date on the latest research on this condition, as well as some patient resources to help your patients navigate their diagnosis.
Next-generation Enhanced Visibility of NMIBC in the Operating Room
July 2023
Blue Light Cystoscopy (BLC®), which uses fluorescence to color tumors or lesions vivid pink, while healthy tissue remains blue, allows the visualization of bladder cancer that is not readily apparent when using White Light Cystoscopy (WLC) alone. Mild discoloration, flat lesions or papillary lesions that are not particularly raised can be missed when only WLC is used. With BLC, the borders of the harder-to-see areas can be seen more easily because of the fluorescence. Better visibility can mean a more complete resection. Kristen Scarpato, M.D., M.P.H., Associate Professor of Urology at Vanderbilt University Medical Center, who is experienced with Blue Light Cystoscopy (BLC®), shares her enthusiasm about the practical benefits of the improvements of the availability of BLC SAPHIRA equipment.
The Latest in Bladder Cancer
AUANews | October 2025
Contemporary Challenges in Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer
By using a strict definition of BCG-unresponsive disease for clinical application, several challenges emerge in this evolving disease space that limit patient access to novel therapies based on label indications.
AUANews
AUA Journals
